HOME >> BIOLOGY >> NEWS
OSA symptoms more common among African-American women than Caucasians

WESTCHESTER, Ill. In a study that examined the relationship between race, menopausal status and symptoms of obstructive sleep apnea (OSA), middle-aged African-American women were found to be more likely to experience OSA symptoms than their Caucasian counterparts, according to a research abstract that will be presented Monday at SLEEP 2007, the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS).

Elizabeth Beothy, of the University of Pennsylvania, who authored the study, administered a questionnaire to 269 subjects, with an average age of 48, and 49.4 percent of which were African-American. Further, 37.5 percent of women were pre-menopausal, 43 percent in the menopausal transition and 19.5 percent post-menopausal.

The mean apnea score among African-American women was nearly double that of Caucasian women. Menopausal status was not a significant predictor of OSA symptoms. Race remained a significant predictor of OSA symptoms after adjustment for current body mass index (BMI), BMI change over time and menopausal status.

"Although menopausal status did not predict OSA symptoms, OSA symptoms on our cohort of menopausal women increased with higher BMI and larger BMI increases over time," said Beothy, who added that studies to document whether OSA is more common among African-American women than Caucasian women should be performed to further investigate these findings.

OSA affects an estimated 15 million to 20 million Americans, as well as millions more who remain undiagnosed and untreated.

Scientific evidence shows that CPAP is the best treatment for sleep apnea. CPAP provides a steady stream of pressurized air to patients through a mask that they wear during sleep. This airflow keeps the airway open, preventing the pauses in breathing that characterize OSA and restoring normal oxygen levels.


'"/>

Contact: Jim Arcuri
jarcuri@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
11-Jun-2007


Page: 1

Related biology news :

1. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
2. MIT researchers reverse symptoms in mice of leading inherited cause of mental retardation
3. Latest data shows MabThera provides significant, sustained relief from symptoms of RA
4. Gene malfunctions cause schizophrenia, depression symptoms in mice
5. Switching genes to overdrive improves muscular dystrophy symptoms in mice
6. Reversal of symptoms in an autism spectrum disorder
7. Malaria drug may treat metabolic syndromes many symptoms
8. Brain protein improves stroke symptoms in rats, even when injected after 3 days
9. Rush and UCSF found gene therapy appeared to reduce symptoms of Parkinsons by 40 percent
10. Epilepsy drug eases symptoms of inherited disorder that weakens muscles
11. Researchers reverse Parkinsons symptoms in animal models

Post Your Comments:
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
(Date:8/12/2015)... 2015  New research unveiled at Black Hat ... to steal users, fingerprints. Information released today by ... scanners on mobile devices, making the security of ... on mobile devices, HYPR Corp. recently released a ... systems with strong cryptographic security. More information on ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: